← Browse by Condition
Medical Condition

hidradenitis suppurativa

Total Trials
7
Recruiting Now
7
Trial Phases
Phase 2, Phase 1

ClinicalMetric tracks all active clinical trials for hidradenitis suppurativa sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — hidradenitis suppurativa Clinical Trials

How many clinical trials are currently recruiting for hidradenitis suppurativa?
ClinicalMetric currently tracks 7 actively recruiting clinical trials for hidradenitis suppurativa, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 7. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for hidradenitis suppurativa?
hidradenitis suppurativa research spans Phase 1 (1 trial), Phase 2 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a hidradenitis suppurativa clinical trial?
Eligibility criteria for hidradenitis suppurativa trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
3
Top Sponsors
Takeda 1 trial
AbbVie 1 trial
Novartis Pharmaceuticals 1 trial
Assistance Publique - Hôpitaux de Paris 1 trial
Sanofi 1 trial

Recruiting Clinical Trials

NCT07244263 Phase 2
Recruiting
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
Enrollment
90 pts
Location
United States, Austr...
Sponsor
Takeda
View Trial →
NCT07136467
Recruiting
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
Enrollment
2,795 pts
Location
Argentina, Canada, C...
Sponsor
AbbVie
View Trial →
NCT07543419
Recruiting
Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population
Enrollment
250 pts
Location
Italy
Sponsor
Novartis Pharmaceuticals
View Trial →
NCT06599411
Recruiting
Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases
Enrollment
830 pts
Location
France
Sponsor
Assistance Publique - Hôpitaux...
View Trial →
NCT07225569 Phase 2
Recruiting
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Enrollment
144 pts
Location
United States, Argen...
Sponsor
Sanofi
View Trial →
NCT06082323 Phase 1
Recruiting
A Single and Multiple Ascending Dose Trial of LT-002-158 Tablets in Healthy Adult Volunteers
Enrollment
127 pts
Location
China
Sponsor
Leadingtac Pharmaceutical (Sha...
View Trial →
NCT07077902 Phase 2
Recruiting
A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa
Enrollment
10 pts
Location
United States
Sponsor
Tulane University
View Trial →

Related Conditions

atopic dermatitis (2) non segmental vitiligo nsv (1) alopecia areata (1) psoriasis (1) lichen planus (1) cutaneous lupus (1) dermatomyositis (1) cutaneaous scleroderma (1) neutrophilic dermatosis (1) cutaneous granulomatosis (1) active leprosy (1) autoimmune bullous dermatosis (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology